Literature DB >> 24465011

Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Jinsong Zhang1, S Munir Alam, Hilary Bouton-Verville, Yao Chen, Amanda Newman, Shelley Stewart, Frederick H Jaeger, David C Montefiori, S Moses Dennison, Barton F Haynes, Laurent Verkoczy.   

Abstract

A goal of HIV-1 vaccine development is to elicit broadly neutralizing Abs (BnAbs), but current immunization strategies fail to induce BnAbs, and for unknown reasons, often induce nonneutralizing Abs instead. To explore potential host genetic contributions controlling Ab responses to the HIV-1 Envelope, we have used congenic strains to identify a critical role for MHC class II restriction in modulating Ab responses to the membrane proximal external region (MPER) of gp41, a key vaccine target. Immunized H-2(d)-congenic strains had more rapid, sustained, and elevated MPER(+) Ab titers than those bearing other haplotypes, regardless of immunogen, adjuvant, or prime or boost regimen used, including formulations designed to provide T cell help. H-2(d)-restricted MPER(+) serum Ab responses depended on CD4 TH interactions with class II (as revealed in immunized intra-H-2(d/b) congenic or CD154(-/-) H-2(d) strains, and by selective abrogation of MPER restimulated, H-2(d)-restricted primed splenocytes by class II-blocking Abs), and failed to neutralize HIV-1 in the TZM-b/l neutralization assay, coinciding with lack of specificity for an aspartate residue in the neutralization core of BnAb 2F5. Unexpectedly, H-2(d)-restricted MPER(+) responses functionally mapped to a core TH epitope partially overlapping the 2F5/z13/4E10 BnAb epitopes as well as nonneutralizing B cell-Ab binding residues. We propose that class II restriction contributes to the general heterogeneity of nonneutralizing gp41 responses induced by Envelope. Moreover, the proximity of TH and B cell epitopes in this restriction may have to be considered in redesigning minimal MPER immunogens aimed at exclusively binding BnAb epitopes and triggering MPER(+) BnAbs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24465011      PMCID: PMC3936991          DOI: 10.4049/jimmunol.1302511

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Authors:  D Jankovic; P Caspar; M Zweig; M Garcia-Moll; S D Showalter; F R Vogel; A Sher
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120.

Authors:  Lyn M Daly; Patricia A Johnson; Graham Donnelly; Carolyn Nicolson; James Robertson; Kingston H G Mills
Journal:  Vaccine       Date:  2005-01-04       Impact factor: 3.641

Review 3.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors:  Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal:  Hum Antibodies       Date:  2005

4.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

5.  Immunogenicity of peptides for B cells is not impaired by overlapping T-cell epitope topology.

Authors:  D P Harris; H M Vordermeier; A Arya; K Bogdan; C Moreno; J Ivanyi
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

6.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Authors:  Rosa M F Cardoso; Michael B Zwick; Robyn L Stanfield; Renate Kunert; James M Binley; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

7.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

8.  HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  G J Gorse; L Corey; G B Patel; M Mandava; R H Hsieh; T J Matthews; M C Walker; M J McElrath; P W Berman; M M Eibl; R B Belshe
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-20       Impact factor: 2.205

9.  Impaired antibody responses in H-2Ab mice.

Authors:  S Gustavsson; S Hjulström-Chomez; B M Lidström; N Ahlborg; R Andersson; B Heyman
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

Review 10.  The Th1-Th2 hypothesis of HIV infection: new insights.

Authors:  M Clerici; G M Shearer
Journal:  Immunol Today       Date:  1994-12
View more
  11 in total

1.  HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.

Authors:  Todd Bradley; Guang Yang; Olga Ilkayeva; T Matt Holl; Ruijun Zhang; Jinsong Zhang; Sampa Santra; Christopher B Fox; Steve G Reed; Robert Parks; Cindy M Bowman; Hilary Bouton-Verville; Laura L Sutherland; Richard M Scearce; Nathan Vandergrift; Thomas B Kepler; M Anthony Moody; Hua-Xin Liao; S Munir Alam; Roger McLendon; Jeffrey I Everitt; Christopher B Newgard; Laurent Verkoczy; Garnett Kelsoe; Barton F Haynes
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

Review 2.  Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.

Authors:  Laurent Verkoczy; Marilyn Diaz
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

3.  Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

Authors:  Melissa C Hanson; Wuhbet Abraham; Monica P Crespo; Stephanie H Chen; Haipeng Liu; Greg Lee Szeto; Mikyung Kim; Ellis L Reinherz; Darrell J Irvine
Journal:  Vaccine       Date:  2015-01-02       Impact factor: 3.641

Review 4.  Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Authors:  Laurent Verkoczy
Journal:  Adv Immunol       Date:  2017       Impact factor: 3.543

5.  Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Authors:  Ruijun Zhang; Laurent Verkoczy; Kevin Wiehe; S Munir Alam; Nathan I Nicely; Sampa Santra; Todd Bradley; Charles W Pemble; Jinsong Zhang; Feng Gao; David C Montefiori; Hilary Bouton-Verville; Garnett Kelsoe; Kevin Larimore; Phillip D Greenberg; Robert Parks; Andrew Foulger; Jessica N Peel; Kan Luo; Xiaozhi Lu; Ashley M Trama; Nathan Vandergrift; Georgia D Tomaras; Thomas B Kepler; M Anthony Moody; Hua-Xin Liao; Barton F Haynes
Journal:  Sci Transl Med       Date:  2016-04-27       Impact factor: 17.956

6.  A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.

Authors:  Ethan Poteet; Phoebe Lewis; Feng Li; Sheng Zhang; Jianhua Gu; Changyi Chen; Sam On Ho; Thai Do; SuMing Chiang; Gary Fujii; Qizhi Yao
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

7.  HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.

Authors:  Laurent Verkoczy; Garnett Kelsoe; Barton F Haynes
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

8.  Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Authors:  Luis M Molinos-Albert; Eneritz Bilbao; Luis Agulló; Silvia Marfil; Elisabet García; Maria Luisa Rodríguez de la Concepción; Nuria Izquierdo-Useros; Cristina Vilaplana; Jon A Nieto-Garai; F-Xabier Contreras; Martin Floor; Pere J Cardona; Javier Martinez-Picado; Bonaventura Clotet; Jordi Villà-Freixa; Maier Lorizate; Jorge Carrillo; Julià Blanco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

9.  Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.

Authors:  Luke R Donius; Yuxing Cheng; Jaewon Choi; Zhen-Yu J Sun; Melissa Hanson; Michael Zhang; Todd M Gierahn; Susanna Marquez; Mohammed Uduman; Steven H Kleinstein; Darrell Irvine; J Christopher Love; Ellis L Reinherz; Mikyung Kim
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Evaluation of Protective Immunity of Peptide Vaccines Composed of a 15-mer N-terminal Matrix Protein 2 and a Helper T-Cell Epitope Derived from Influenza A Virus.

Authors:  Jeong-Ki Kim; Sinyoung Cheong; Myung Kyu Lee
Journal:  Immune Netw       Date:  2019-07-23       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.